RAB0521
Bovine IL2 / Interleukin-2 ELISA Kit
for serum, plasma and cell culture supernatants
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
41116158
NACRES:
NA.32
Prodotti consigliati
Reattività contro le specie
bovine
Confezionamento
kit of 96 wells (12 strips x 8 wells)
tecniche
ELISA: suitable
input
sample type serum
sample type cell culture supernatant(s)
sample type plasma
assay range
inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL
Metodo di rivelazione
colorimetric
Condizioni di spedizione
wet ice
Temperatura di conservazione
−20°C
Informazioni sul gene
bovine ... IL2(280822)
Descrizione generale
This ELISA antibody pair detects bovine Interleukin-2.
Applicazioni
For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)
Altre note
A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.
Please type the word sample in the text box provided for lot number.
I componenti del kit sono disponibili anche separatamente
N° Catalogo
Descrizione
SDS
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Met. Corr. 1
Codice della classe di stoccaggio
8A - Combustible corrosive hazardous materials
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Francesco Nannini et al.
Scientific reports, 10(1), 19168-19168 (2020-11-07)
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the advantage of in vivo affinity-maturation of V regions prior to library
Liping Qiu et al.
Small (Weinheim an der Bergstrasse, Germany), 14(15), e1703539-e1703539 (2018-03-02)
The activation of tumor-specific effector immune cells is key for successful immunotherapy and vaccination is a powerful strategy to induce such adaptive immune responses. However, the generation of effective anticancer vaccines is challenging. To overcome these challenges, a novel straight-forward
Zhengping Hu et al.
Scientific reports, 8(1), 217-217 (2018-01-11)
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.